The Database Connection

Anne Wojcicki, the CEO and a co-founder of 23andMe, tells Nature's Soapbox Science blog that her company is moving toward working with pharmaceutical companies on phase 4, post-marketing studies. The company's database contains data from about 150,000 customers, the blog adds. "We definitely want to connect more and more with pharma partners to leverage the platform we've created," Wojcicki says. "The example I gave — phase 4 studies, following patients over time, understanding how they are using therapies, collecting quality of life data — it's something that we're perfectly set up to do." She adds that adding a genetic aspect to phase 4 studies could help identify both responders and adverse event subgroups.


Oh yes indeed, Big Sister

Oh yes indeed, Big Sister knows all about how to compile dossiers of health and other life status metrics extrapolated from myriad anecdotal and incidental observations by Google-type unqualified, but no doubt low predictive value, algorithms. Brave new world!

Beg to differ. Drugs surely

Beg to differ. Drugs surely have much to do with enzymes in the liver & receptors on the surface of target organ cells. Target cancer therapies, warfarin, … are solid examples. Partitioned trial population saved Irresa, a lung cancer & CRC drug.